Indefinite Delivery Contract SPE2DR25D9124

The federal contract IDV award SPE2DR25D9124 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications.

This IDC is part of the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) acquisition, which aims to establish multiple regional contracts to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency, U.S. Coast Guard, and U.S. Naval Fleet. The unrestricted, fully competitive solicitation is expected to be issued in March 2024 with a 45-day response period and a total estimated value of $30.3 billion across the multiple awards. The contracts will have a 30-month base period and three 30-month option periods, with awards made on a lowest price technically acceptable basis.